Keros Therapeutics Inc KROS.OQ KROS.O is expected to show no change in quarterly revenue when it reports results on November 8 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Keros Therapeutics Inc is for a loss of $1.28 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Keros Therapeutics Inc is $92.00, above its last closing price of $62.58.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.23 | -1.23 | -1.25 | Missed | -1.5 |
Mar. 31 2024 | -1.30 | -1.35 | -1.21 | Beat | 10.2 |
Dec. 31 2023 | -1.35 | -1.37 | -1.34 | Beat | 2.5 |
Sep. 30 2023 | -1.34 | -1.35 | -1.33 | Beat | 1.3 |
Jun. 30 2023 | -1.33 | -1.34 | -1.27 | Beat | 5.1 |
Jan. 1 0001 | -1.13 | -1.12 | -1.26 | Missed | -12.2 |
Dec. 31 2022 | -1.08 | -1.10 | -1.09 | Beat | 0.7 |
Sep. 30 2022 | -1.23 | -1.23 | -0.92 | Beat | 25.3 |
This summary was machine generated November 6 at 14:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。